vimarsana.com

Research analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) in a report released on Monday. The firm set a “sell” rating on the stock. ONCT has been the subject of several other reports. Brookline Capital Acquisition reaffirmed a “hold” rating on shares of Oncternal Therapeutics in a research report […]

Related Keywords

San Diego ,California ,United States ,Davidf Hale ,Jamesb Breitmeyer , ,Securities Exchange Commission ,Virtu Financial ,Prudential Financial Inc ,Maxim Group ,Waypoint Capital Advisors ,Oncternal Therapeutics Inc ,Mirabella Financial Services ,Richmond Brothers Inc ,Oncternal Therapeutics ,Get Rating ,Capital Acquisition ,Capital Management ,Exchange Commission ,Financial Services ,Capital Advisors ,Oncternal Therapeutics Daily ,Nasdaq Onct ,Conct ,Medical ,Initiated Coverage ,Stocknews Com ,

© 2025 Vimarsana

vimarsana.com © 2020. All Rights Reserved.